Ilunocitinib versus oclacitinib in the atopic dog
3-year-old Labrador with atopic dermatitis. On twice-daily oclacitinib the pruritus resolves, but after reducing to once daily at 14 days it starts scratching again. Switching to ilunocitinib is being considered.
Which statement about ilunocitinib is correct?
chevron_right Show answer and explanation
A. It is a Janus kinase inhibitor given once daily from the start, without a twice-daily induction phase, and it shares the precautions of JAK drugs (minimum age 12 months, infections, neoplasia)
Correct. Ilunocitinib inhibits JAK1, JAK2 and TYK2 and is dosed once daily continuously, avoiding the rebound some dogs show when oclacitinib is reduced. As an immunomodulator, it is not used under 12 months of age or with serious infections or neoplasia.
B. It is a monthly anti-IL-31 monoclonal antibody
That describes lokivetmab, an injectable antibody. Ilunocitinib is a small molecule given orally.
C. It is a calcineurin inhibitor that takes weeks to work
That is ciclosporin. Ilunocitinib, like oclacitinib, reduces pruritus within hours or a few days.
D. It has no immunomodulatory effects, so it is safe in puppies and with active infections
All JAK inhibitors modulate the immune response. Before using it, infections must be controlled and the label's minimum age respected.
lightbulb Key takeaway
If a dog relapses when oclacitinib is reduced to once daily, check triggers first (fleas, infection, food). If there are none, options include a once-daily JAK inhibitor, lokivetmab or ciclosporin. Check the label warnings on vaccination and infections.
Test yourself with 10 random questions
Dermatology · 100 questions, a different test every time
Related questions
Updated: October 31, 2026 · Educational content for veterinary professionals. It does not replace current clinical guidelines or the judgement of the attending veterinarian.